Patent · US Active

1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor

US8741916B2 · kind B2 · utility

0Cited by

31References

34Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Gilles Bignan · Bound Brook, US
Dennis J. Hlasta · Doylestown, US
Richard R. Ryan · Yardley, US

Key dates

Filing date	Feb 14, 2008
Grant date	Jun 3, 2014
Priority date	—
Expiry date	Aug 4, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to novel 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.